Use of antimicrobial agents in United States neonatal and pediatric intensive care patients

Pediatric Infectious Disease Journal

Volumn 24, Issue 9, 2005, Pages 766-773

  Grohskopf, Lisa A ^a,b   Huskins, W Charles ^c   Sinkowitz Cochran, Ronda L ^a   Levine, Gail L ^d   Goldmann, Donald A ^e   Jarvis, William R ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c MAYO CLINIC   (United States)

^d National Association of Children's Hospitals and Related Institutions   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Antibiotics; Neonatal intensive care units; Pediatric intensive care units

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMPHOTERICIN B; AMPICILLIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFONAMIDE; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CHILDHOOD DISEASE; DEMOGRAPHY; DRUG USE; FEMALE; HEALTH SURVEY; HOSPITAL PERSONNEL; HUMAN; INFANT; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; NEWBORN INTENSIVE CARE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; UNITED STATES;

EID: 24944539548     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000178064.55193.1c     Document Type: Article

References (28)

1. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA. 1996;275:234-240.
2. National Nosocomial Infections Surveillance System. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) surveillance report, data summary from January 1996 through December 1997. Am J Infect Control. 1999;27:279-284.
3. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States Hospitals: Project ICARE phase 2. Clin Infect Dis. 1999;29:245-252.
4. Sohn AH, Garrett DO, Sinkowitz-Cochran RL, et al. Prevalence of nosocomial infections in neonatal intensive care unit patients: results from the first national point-prevalence survey. J Pediatr. 2001;139:821-827.
5. Grohskopf LA, Sinkowitz-Cochran RL, Garrett DO, et al. A national point-prevalence survey of pediatric intensive care unit-acquired infections in the United States. J Pediatr. 2002;140:432-438.
6. Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic care facility. Antimicrob Agents Chemother. 1990;34:2193-2199.
7. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993;119:353-358.
8. Rice LB, Eckstein EC, DeVente J, Shales DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis. 1996;23:118-124.
9. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin use in nosocomial Klebsiella. JAMA. 1998;280:1233-1237.
10. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pnemoniae. Infect Control Hosp Epidemiol. 2000;21:455-458.
11. Moreno F, Grota P, Crisp C, et al. Clinical and molecular epidemiology of vancomycin-resistant Enterococcus faecium during its emergence in a city in southern Texas. Clin Infect Dis. 1995;21:1234-1237.
12. Tokars JI, Satake S, Rimland D, et al. The prevalence of colonization with vancomycin-resistant Enterococcus at a Veterans' Affairs institution. Infect Control Hosp Epidemiol. 1999;20:171-175.
13. Dahms RA, Johnson EM, Statz CL, et al. Third-generation cephalosporins and vancomycin as risk factors for post-operative vancomycin-resistant enterococcus infection. Arch Surg. 1998;133:1343-1346.
14. Fridkin SK, Edwards JE, Courval JM, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 adult intensive care units. Ann Intern Med. 2001;135:175-183.
15. Boyce JM, Opal SM, Chow JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol. 1994;32:1148-1153.
16. Morris JG, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med. 1995;123:250-259.
17. Stroud L, Edwards J, Danzig L, Culver D, Gaynes R. Risk factors for mortality associated with enterococcal bloodstream infections. Infect Control Hosp Epidemiol. 1996;17:576-580.
18. Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis. 1993;16:750-755.
19. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40:135-136.
20. Smith TL, Pearson ML, Wilcox KR. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med. 1999;340:493-501.
21. Sievert DM, Boulton ML, Stoltman G, et al. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR. 2002;51:565-567.
22. Shay DK, Goldmann DA, Jarvis WR. Reducing the spread of vancomycin-resistant microorganisms: control of vancomycin-resistant enterococci. Pediatr Clin North Am. 1995;42:703-716.
23. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR. 1995;44(RR-12).
24. Shah SS, Sinkowitz-Cochran RL, Keyserling HL, Jarvis WR. Vancomycin use in pediatric cardiothoracic surgery patients. Pediatr Infect Dis J. 1999;18:558-559.
25. Sinkowitz-Cochran RL, Keyserling HL, Walker TJ, Holland J, Jarvis WR. Epidemiology of vancomycin usage at a children's hospital, 1993-1995. Pediatr Infect Dis J. 1997;16:485-489.
26. Shah SS, Sinkowitz-Cochran RL, Keyserling HL, Jarvis WR. Vancomycin use in pediatric neurosurgery patients. Am J Infect Control. 1999;27:482-487.
27. Hopkins HA, Sinkowitz-Cochran RL, Rudin BA, Keyserling HL, Jarvis WR. Vancomycin use in pediatric hematology-oncology patients. Infect Control Hosp Epidemiol. 2000;21:48-50.
28. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110:285-291.